ArticleScientific reports2026
Menstrual blood-derived mesenchymal stromal cell extracellular vesicles stimulate chondrocytes and cartilage extracellular matrix synthesis in vitro.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Human mesenchymal stromal cells are frequently studied for the development of novel technologies for preventing osteoarthritis development or repairing cartilage tissue after traumas. Menstrual blood-derived mesenchymal stromal cells (MenSCs) are less studied, however, they possess a strong therapeutic potential due to their secretome, including extracellular vesicles (EVs). The aim of this study was to evaluate the potential of MenSC-EVs in stimulating chondrocyte functions, as well as cartilage tissue repair. Chondrocyte proliferation, morphology (holomonitor), sex hormone receptor expression (ELISA, RT-qPCR), and chondrogenic capacity (RT-qPCR, histology) were evaluated after 3 days of MenSC-EV treatment. Cartilage explants were isolated and treated with EVs for 3 days and cultured for 3 and 7 days under inflammatory (IL-1β) or regenerative (TGF-β3) conditions. Cartilage oligomeric matrix protein (COMP) secretion and glycosaminoglycan (GAG) release were assessed by ELISA and spectrophotometry, with extracellular matrix (ECM) deposition evaluated by histology/immunohistochemistry, infrared absorption spectroscopy and gene expression by RT-qPCR. Cytokine and growth factor secretion were quantified in explant and chondrocyte culture supernatants using multiplexed Luminex assays. MenSC-EVs did not affect chondrocyte migration/motility, speed/perimeter and proliferation after 7 days. However, EVs increased progesterone receptor expression, as well as ECM production together with collagen type II and TGF-β3 receptor gene expression in chondrocytes after 21 days with TGF-β3. Cartilage degradation was diminished after treatment with MenSC-EVs according to lower levels of COMP and GAGs released under conventional or inflammatory conditions. Moreover, MenSC-EVs did not significantly affect inflammatory cytokine secretion in cartilage explants stimulated or not with IL-1β and in chondrocyte monolayer, except for secretion of IL-6. In addition, cartilage ECM components (collagen II and aggrecan), as well as TGF-β3 receptor gene expression were significantly higher in MenSC-EV treated cartilage explant samples, as compared to non-treated. Infrared absorption spectroscopy of MenSC-EV treated cartilage explants corroborated ECM restoration, with samples exhibiting higher amide I/II intensities and a stronger carbohydrate-associated band near 1030 cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.